CX3CL1 expression is associated with poor outcome in breast cancer patients
Publication in refereed journal

香港中文大學研究人員
作者已離職


引用次數
替代計量分析
.

其它資訊
摘要The significance of chemokines in cancer biology has been widely recognized in recent years. CX3CL1 is a unique subclass of chemokine with complex functions, including recruitment of anti-tumor leukocytes and promoting cancer survival, thus affecting cancer progression in both the directions. It is not clear how these different functions interact in breast cancers. This is further complicated by the heterogeneity of breast cancer, and differential association of CX3CL1 with different subgroups could be present. There is only limited knowledge of CX3CL1 expression profile, its relationship with different biological features, subtypes, and outcomes in breast cancers. In this study, CX3CL1 expression was examined in a large cohort of breast cancers by immunohistochemistry and its association with clinicopathological factors, biomarker expression, and impact on patients' survival was assessed. High CX3CL1 expression was detected in 33.3 % (252/757) of primary invasive cancers. In line with its chemo-attractant function, CX3CL1 expression correlated positively with increased tumor infiltrating lymphocytes (TIL) (p = 0.005). In addition, CX3CL1 also correlated positively with adverse features in breast cancers, including lymph node involvement (p = 0.007), high Ki67 (p = 0.002), alpha-B crystallin expression (p = 0.008), and luminal B (worse prognosis luminal cancers) subtype (p = 0.024). Consistently, breast cancers with high expression of CX3CL1 were found to have a poorer overall survival (chi(2) = 4.797, p = 0.029). Interestingly, the adverse effect of CX3CL1 on outcome appeared to be more prominent in cancers with low TIL. These findings indicated that CX3CL1 could also have a pro-tumor role in breast cancer, despite its previously suggested role in enhancing anti-tumor immunity. The results highlighted the complicated functions of CX3CL1 in breast carcinogenesis. Further studies are needed to clarify the relative contribution of these anti- and pro-tumor functions in order to understand the true prognostic and potential therapeutic values of CX3CL1.
著者Tsang JYS, Ni YB, Chan SK, Shao MM, Kwok YK, Chan KW, Tan PH, Tse GM
期刊名稱Breast Cancer Research and Treatment
出版年份2013
月份8
日期1
卷號140
期次3
出版社Springer Verlag (Germany)
頁次495 - 504
國際標準期刊號0167-6806
電子國際標準期刊號1573-7217
語言英式英語
關鍵詞Biomarker; Breast cancer; CX3CL1; Patients survival
Web of Science 學科類別Oncology; ONCOLOGY

上次更新時間 2021-22-01 於 00:20